Omrix Biopharmaceuticals, Inc. Initiates Phase I/II Clinical Trial to Evaluate Safety and Initial Efficacy of Adhexil™ in Preventing and/or Reducing Post-Operative Adhesions in Patients Undergoing Gynecological Surgery
24 Oct 2007
CollaborateImmunotherapy
NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or "The Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, announced today that it has initiated enrollment of patients in a Phase I/II clinical trial for Adhexil™, the Company's proprietary adhesion prevention product. The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The clinical trial will be conducted over a one-year period and will enroll 25 patients with bilateral ovarian disease and identified adhesions across four centers in Europe and the U.S.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.